When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
DBVT - Aimmune Therapeutics: Do Not Tender Your Shares To Nestle
DBV Technologies S.A.
AIMT's stock fell precipitously amid the COVID-19 pandemic, despite receiving FDA approval for its Palforzia treatment (the first FDA approved treatment for peanut allergies).
Nestle has commenced a tender offer to purchase shares of AIMT at $34.50 per share and it is trying to take advantage of the unwarranted selloff.
Given recent developments with AIMT and its competitor, DBV Technologies, I believe this offer price is woefully inadequate.